Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Altered pharmacokinetics and excessive hypotensive effect of candesartan in a patient with the CYP2C91/3 genotype.

Clinical pharmacology and therapeutics - 1 Nov 2003

Uchida Shinya, Watanabe Hiroshi, Nishio Shinichiro, Hashimoto Hisakuni, Yamazaki Keisuke, Hayashi Hideharu, Ohashi Kyoichi

Abstract excerpt

An 89-year-old man with severe hypertension (190/82 mm Hg) and chronic heart failure (New York Heart Association class II) despite treatment with benidipine, doxazosin mesylate (INN, doxazosin), and furosemide was given oral candesartan cilexetil (4 mg/d), an angiotensin II type 1 receptor blocker metabolized via cytochrome p450 (CYP) 2C9. Two days later, he started to have severe dizziness and returned to the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiotensin II Type 1 Receptor Blockers
Share to Antihypertensive Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Area Under Curve

Share to Benzimidazoles

Share to Biphenyl Compounds

Share to Cytochrome P-450 CYP2C9

Share to Heart Failure

Share to Tetrazoles

Source

Identifiers

PMID: 14586391
DOI: 10.1016/j.clpt.2003.08.001

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Altered pharmacokinetics and excessive hypotensive effect of candesartan in a patient with the CYP2C91/3 genotype.PMID 14586391Read ↗

CYP2C9*3 influences the metabolism and the drug-interaction of candesartan in vitro.Semantic proximity Read ↗

CYP2C9*3 allelic variant is associated with metabolism of irbesartan in Chinese population.Semantic proximity Read ↗

Effects of the CYP2C9*13 allele on the pharmacokinetics of losartan in healthy male subjects.Semantic proximity Read ↗

Effect of the single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects.Semantic proximity Read ↗

Substrate-dependent functional alterations of seven CYP2C9 variants found in Japanese subjects.Semantic proximity Read ↗

Genetic variations of CYP2C9 in 724 Japanese individuals and their impact on the antihypertensive effects of losartan.Semantic proximity Read ↗

CYP2C9 3 and 13 alleles significantly affect the pharmacokinetics of irbesartan in healthy Korean subjects.Semantic proximity Read ↗

Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes.Semantic proximity Read ↗

Frequency of CYP2C9 alleles in Koreans and their effects on losartan pharmacokinetics.Semantic proximity Read ↗

Effects of CYP2C9*1/*3 and *1/*13 on the pharmacokinetics of losartan and its active metabolite E-3174.Semantic proximity Read ↗

Effects of CYP2C9*3 and *13 alleles on the pharmacokinetics and pharmacodynamics of glipizide in healthy Korean subjects.Semantic proximity Read ↗

CYP2C9 genotype modifies activity of the renin-angiotensin-aldosterone system in hypertensive men.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.